retatrutide and diabetes Helped Adults With or Heart Disease Lose Up to 20 Percent of Their Weight, Study Finds New Triple-Action Drug Retatrutide Shows

Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction

Table 5 Clinical effectiveness of the intervention for body weight reduction

The safety profile is reassuring

This proportion was also compared between specific types of GLP-1RA received, diabetes status, indication of therapy, concurrent comorbidity using Wilcoxon rank sum, and Kruskal-Wallis tests

Medications That Mimic or Enhance GLP-1 Signaling Beyond GLP-1 receptor agonists, several medication classes modulate appetite and metabolic rate through overlapping pathways